Morphinan compounds

Details Morphinan compounds Morphinan compounds

2011-07-05

2011-07-05

Aulakh, Charanjit (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S074000

Reexamination Certificate

active

07973049

ABSTRACT:
This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1receptor agonist that also has NMDA antagonist activity.

REFERENCES:
patent: 4316888 (1982-02-01), Nelson
patent: 4446140 (1984-05-01), Nelson
patent: 4694010 (1987-09-01), Musacchio et al.
patent: 4898860 (1990-02-01), Musacchio et al.
patent: 5166207 (1992-11-01), Smith
patent: 5304121 (1994-04-01), Sahatjian
patent: 5336980 (1994-08-01), Levers
patent: 5350756 (1994-09-01), Smith
patent: 5366980 (1994-11-01), Smith
patent: 5863927 (1999-01-01), Smith et al.
patent: 5886026 (1999-03-01), Hunter et al.
patent: 6099562 (2000-08-01), Ding et al.
patent: 6197830 (2001-03-01), Frome
patent: 6207164 (2001-03-01), Kreuter et al.
patent: 6221335 (2001-04-01), Foster
patent: 6440710 (2002-08-01), Keinan et al.
patent: RE38115 (2003-05-01), Smith et al.
patent: 6583152 (2003-06-01), Sosnowski et al.
patent: 6603008 (2003-08-01), Ando et al.
patent: 6803031 (2004-10-01), Rabinowitz et al.
patent: 7014866 (2006-03-01), Infeld et al.
patent: 7114547 (2006-10-01), Sullivan et al.
patent: 7517990 (2009-04-01), Ito et al.
patent: 2001/0044446 (2001-11-01), Phillips et al.
patent: 2002/0103109 (2002-08-01), Glick et al.
patent: 2004/0087479 (2004-05-01), Sosnowski et al.
patent: 2005/0129783 (2005-06-01), McCleary et al.
patent: 2005/0203125 (2005-09-01), Yakatan et al.
patent: 2006/0079502 (2006-04-01), Lang
patent: 2006/0094744 (2006-05-01), Maryanoff et al.
patent: 2007/0082929 (2007-04-01), Gant et al.
patent: 2007/0191411 (2007-08-01), Smith
patent: 2007/0197695 (2007-08-01), Potyen et al.
patent: 2008/0103122 (2008-05-01), Veltri
patent: WO 95/26325 (1995-10-01), None
patent: WO 2007/118651 (2007-10-01), None
Authorized officer Lee W. Young, International Search Report/Written Opinion in PCT/US10/27990 mailed Mar. 19, 2010, 11 pages.
“Combination of dextromethorphan and quinidine sulphate” [online]. Prous Science Integrity, [retrieved on Apr. 23, 2007]. Retrieved from the Internet: <URL: http://integrity.prous.com/integrity/servlet/xmlxsl/pk—prodlist.xml—. . . >.
Anastasia et al., “Simple and selective one-pot replacement of the N-methyl group of tertiary amines by quaternization and demethylation with sodium sulfide or potassium thioacetate: an application to the synthesis of pergolide.”J. Chem. Soc., Perkin Trans.1, 2001, 19:2398-2403.
Freireich et al., “Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man,”Cancer Chemother. Rep., 1966, 50:219-244.
Ganapathy et al., “Molecular and ligand-binding characterization of the s-receptor in the Jurkat human T lymphocyte cell line,”J. Pharmacol Exp Ther., 1999, 289:251-260.
Gannes et al., “Natural abundance variations in stable isotopes and their potential uses in animal physiological ecology,”Comp. Biochem. Physiol. A Mol. Integr. Physiol., 1998, 119:725-737.
Goldman et al., “Differentiation of [.H] phencyclidine and (+)-[.H]SKF-10047 binding sites in rat cerebral cortex,”FEBS Lett., 1985, 190:333-336.
Heinkele et al., “Synthesis of [2H3]-dextromethorphan and its major urinary metabolites [2H3]—dextrorphan and [2H3]—dextrorphan- □-glucuronide,”J. Labelled Compounds Radiopharmaceuticals, 2002, 45(13):1153-1158.
Heinkele and Muerdter, “Synthesis of [2H]-labelled phase-I-metabolites using 1[2H]-pyridinium hydrochloride,”J. Labelled Compounds Radiopharmaceuticals, 2005, 48(6):457-461.
Houston et al., “Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices,”Drug Metab. Rev., 1997, 29:891-922.
Houston, “Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance,”Biochem. Pharmacol., 1994, 47:1469-1479.
Iwatsubo et al., “Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data,”Pharmacol. Ther., 1997, 73:147-171.
Kim et al., “Anticonvulsant effects of new morphinan derivatives,”Bioorganic&Medicinal Chemistry Letters, 2001, 11(13):1651-1654.
Lave et al., “The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans,”Pharm. Res., 1997, 14:152-155.
Miller et al., “Dextromethorphan psychosis, dependence and physical withdrawal,”Addict Biol., 2005, 10(4):325-327.
Newman et al., “Synthesis and evaluation of 3-substituted 17-methylmorphinan analogs as potential anticonvulsant agents,”J. Med. Chem., 1992, 35(22):4135-4142.
Nicholson et al., “Evaluation of the reinforcing properties and phencyclidine-like discriminative stimulus effects of dextromethorphan and dextrorphan in rats and rhesus monkeys,”Psychopharmacology(Berl), 1999, 146(1):49-59.
Obach, “Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes,”Drug Metab. Disp., 1999, 27:1350.
Pender et al., “Toxicity with dextromethorphan-containing preparations: a literature review and report of two additional cases,”Pediatr. Emerg. Care, 1991, 7:163-167.
Sawa et al., “Abnormal osmium tetroxide oxidation of N-meythlmorphinan derivatives,”Tetrahedron, 1975, 31(8):953-956.
Scientific Tables, 1970, Geigy Pharmaceuticals, Ardsley, N.Y., p. 537-8.
Siegel et al., “Binding of the radiolabeled glycine site antagonist [3H]MDS105,519 to homomeric NMDA-NR1a receptors,”Eur. J. Pharmacol., 1996, 312(3):357-365.
Wada et al., “[Natural abundance of carbon, nitrogen, and hydrogen isotope ratios in biogenic substances: present and future],”Seikagaku, 1994, 66:15.
Zawertailo et al., “Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study,”J. Clin. Psychopharmacol., 1998, 18(4):332-337.
Bölcskei et al., “Synthesis of Deuterated dextromethorphan derivatives,”Arkivok, 2008, 3:182-193.
Fisher et al., “The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism,”Curr. Opin. Drug Disc. Dev., 2006, 9(1):101-109.
Eichhold et al., “Highly sensitive high-performance liquid chromatographic-tandem mass spectrometric method for the analysis of dextromethorphan in human plasma,”J. Chromatography B, 1997, 698:147-154.
Foster, “Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design,”Adv. Drug Res., 1985, 14:2-40.
Kushner et al., “Pharmacological Uses and Perspectives of Heavy Water and Deuterated Compounds,”Can. J. Physiol. Pharmacol., 1999, 77:79-88.
Authorized officer Eva Brell, International Search Report/Written Opinion in PCT/US2008/062089 mailed Aug. 12, 2008, 11 pages.
Authorized officer Philippe Becamel, International Preliminary Report on Patentability in PCT/US2008/062089 mailed Nov. 12, 2009, 8 pages.
“Patient Information: Dextromethorphan,”Medline Plus, Last Revised Dec. 1, 2008, 6 pages.
“Promethazine HCL and Dextromethorphan Hydrobromide—promethazine hydrochloride and dextromethorphan hydrobromide solution,”ANI Pharmaceuticals, Inc., Last Revised May 2008, 6 pages.
“Promethazine Hydrochloride and Dextromethorphan Hydrobromide— promethazine hydrochloride and dextromethorphan hydrobromide syrup,”Actavis Mid Atlantic LLC, Last Revised Jun. 2006, 6 pages.
Takashima et al., “Evaluation of Dextromethorphan Metabolism Using Hepatocytes from CYP2D6 Poor and Extensive Metabolizers,”Drug Metab. Pharmacokinet., 2005, 20(3):177-182.
Barnhart, “The Uri

Affiliated with

Also associated with

Rating

Morphinan compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Morphinan compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Morphinan compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2684932